)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
NextCure (NXTC) investor relations material
NextCure Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary5 Nov, 2025
Executive summary
Advanced clinical-stage oncology programs, SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC), both in Phase 1 trials with proof-of-concept data expected in 1H 2026.
U.S. enrollment began for SIM0505 and FDA cleared LNCB74 protocol amendment for higher dose escalation.
Operations restructured in March 2024, pausing internal manufacturing and reducing workforce by 37% to prioritize key programs.
Entered a license agreement with Zaiming for SIM0505, incurring $17M in upfront and near-term payments, expensed as R&D.
No product revenue to date; operations funded by equity offerings and prior collaboration payments.
Financial highlights
Net loss for Q3 2025 was $8.6M, down from $11.5M in Q3 2024; nine-month net loss was $46.4M, up from $44.1M year-over-year due to license agreement costs.
Research and development expenses for the nine months ended September 30, 2025 increased by $5.5M year-over-year, primarily due to the $17M Zaiming license.
General and administrative expenses decreased by $2.4M for the nine months ended September 30, 2025, mainly from lower personnel and insurance costs.
Cash, cash equivalents, and marketable securities totaled $29.1M as of September 30, 2025, down from $68.6M at December 31, 2024.
Net cash used in operating activities was $42.0M for the nine months ended September 30, 2025.
Outlook and guidance
Current cash resources are not sufficient to fund operations for one year beyond the financial statement issuance date, raising substantial doubt about going concern status.
Additional capital will be required in the immediate term to continue operations and advance clinical programs.
If sufficient funds are not raised, further cost-cutting, program delays, or workforce reductions may be necessary.
Proof of concept data for SIM0505 and LNCB74 anticipated in the first half of 2026.
Current financial resources are expected to fund operations and capital expenditures into mid-2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next NextCure earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
NextCure Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomedicines to address cancer and other immune-related diseases by restoring normal immune function. The company's pipeline includes NC410, designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody targeting B7-H4, a protein found on various tumor types; and NC525, which targets LAIR-1 to eliminate AML blast cells and leukemic stem cells while sparing normal blood cells. NextCure's research also extends to preclinical evaluations of additional immunomodulatory molecules. NextCure is headquartered in Beltsville, Maryland, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage